

# UBS Equity China Opportunity I-A1-acc


## Fund Fact Sheet

UBS Equity Funds > UBS Opportunity Equity Funds > UBS (Lux) Equity Fund - China Opportunity (USD)

### Fund description

- Very actively managed equity fund based on a concentrated equity portfolio investing in selected Chinese companies
- The manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
- Diversified across sectors offering broad coverage of the Chinese market

### Performance (basis USD, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

Name of fund	<b>UBS (Lux) Equity Fund - China Opportunity (USD)</b>
Share class	UBS (Lux) Equity Fund - China Opportunity (USD) I-A1-acc
ISIN	LU1017642064
Bloomberg	SBCEIA1 LX
Currency of fund / share class	USD/USD
Launch date	29.01.2014
Ongoing charges p.a. <sup>1</sup>	1.22%
Issue/redemption	daily
Swing pricing	yes
Accounting year end	30 November
Benchmark <sup>2</sup>	MSCI China 10/40 (net div. reinv.)
Distribution	Reinvestment
Management fee p.a.	0.960%
Minimum investment	—
Name of the Management Company	UBS Fund Management (Luxembourg) S.A., Luxembourg
Fund domicile	Luxembourg

<sup>1</sup> as at 11.03.2021

<sup>2</sup> Reference index change on 01.01.2018 - old: MSCI China (net div re), new: MSCI China 10/40 (net div. re).

### Fund Statistics

Net asset value (USD, 30.06.2021)	295.17
Last 12 months (USD) – high	354.47
– low	260.24
Total fund assets (USD m)	14 103.95
Share class assets (USD m)	1 283.76

in %	1 year	3 years	5 years	Ø p.a. 3 years	Ø p.a. 5 years
Portfolio (USD)	13.42	46.28	163.52	13.52	21.38
Benchmark <sup>2</sup>	31.58	36.25	117.61	10.86	16.82

The performance shown does not take account of any commissions, entry or exit charges.

- <sup>1</sup> These figures refer to the past. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Source for all data and charts (if not indicated otherwise): UBS Asset Management.  
<sup>2</sup> Reference Index in currency of share class (without costs)

in %	01.2021	02.2021	03.2021	04.2021	05.2021	06.2021
Portfolio (USD)	6.18	-1.58	-6.63	2.23	-1.05	-3.30
Benchmark	6.09	-0.40	-6.20	1.28	1.47	0.30

### Key Figures

	2 years	3 years	5 years
Beta	0.80	0.89	0.88
Correlation	0.91	0.94	0.94
Volatility <sup>1</sup>			
– Portfolio	14.39%	18.46%	16.74%
– Benchmark	16.20%	19.48%	17.73%
Tracking error (ex post)	6.88%	6.81%	6.19%
Information ratio	-0.42%	0.39%	0.74%
Sharpe ratio	1.16	0.66	1.20
Risk free rate	0.85%	1.37%	1.29%
R2	0.82	0.88	0.88

<sup>1</sup> Annualised standard deviation

### For more information

Phone: +352-45-12 11

Internet: [www.ubs.com/luxembourg/funds](http://www.ubs.com/luxembourg/funds)

Contact your client advisor

### Portfolio management representatives

Bin Shi

Morris Wu

Denise Cheung

# UBS Equity China Opportunity I-A1-acc

## Sector exposure (%)

	Portfolio	Deviation from index
Financial Services	20.25	+5.6
Consumer Discretionary	17.43	-15.5
Communication Services	16.04	+2.0
Consumer Staples	12.91	+7.6
Health Care	9.73	+0.5
Real estate	5.06	+0.6
Information Technology	3.43	-4.0
Industrials	2.18	-3.4
Materials	0.80	-2.0
Utility	0.80	-1.4
Energy	0.00	-1.4
Others	11.37	+11.4

## Largest over- / underweights (%)

	Deviation from index
KWEICHOW MOUTAI CO LTD	5.84
NETEASE INC	4.10
HONG KONG EXCHANGES & CLEARING LTD	3.21
CHINA MERCHANTS BANK CO LTD	2.95
LI NING CO LTD	2.95

## 10 largest equity positions (%)

	Portfolio
TENCENT HOLDINGS LTD	9.72
ALIBABA GROUP HOLDING LTD	9.45
KWEICHOW MOUTAI A CNY1	6.71
NETEASE INC-ADR	5.77
PING AN INSURANCE H CNY1	4.82
CHINA MERCHANTS BANK CNY1	4.14
LI NING CO LTD	3.93
HONG KONG EXCHANGES & CLEAR HKD1	3.22
CSPC PHARMACEUTICAL GROUP LT	3.08
PING AN BANK CO LTD A	3.00

## Benefits

Easy access to investment opportunities provided by a rapidly growing Chinese economy. Investors gain access to all classes of shares providing China equity exposure: A, B and H shares as well as Red Chips

Due to the significant deviation from the reference index, the fund offers the potential to outperform the reference index. Investors benefit from UBS being one of the few asset managers with a truly global investment platform

The experienced portfolio management team can leverage local investment expertise in the Chinese market via our joint venture UBS SDIC in China

## Risks

UBS Opportunity Equity Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** For professional clients / qualified investors only. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. The product described herein aligns to Article 6 of Regulation (EU) 2019/2088. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. **Luxembourg:** Prospectuses, key investor information (KIID), the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from Northern Trust Global Services Limited, Luxembourg Branch, 6, rue Lou Hemmer, L-1748 Senningerberg or from UBS Europe SE, Luxembourg Branch, P.O. Box 2, L-2010 Luxembourg and online at [www.ubs.com/funds](http://www.ubs.com/funds). A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [ubs.com/am-glossary](http://ubs.com/am-glossary). © UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.